Re: Report Of Exempt Distribution.

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10534 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Report Of Exempt Distribution.

in response to

Re: Report Of Exempt Distribution.

tada

posted on Apr 18, 2024 05:25AM

tada, should Resverlogix fail, the royalty-preferred shares are worth zero.

Zenith can survive with or without Resverlogix's royalty-preferred shares. Zenith is not dependent on RVX's survival.

I'm still betting that Resverlogix will survive. My glass is still half full for RVX!